BioWorld

May 16, 2011

You're Fired! A Quantitative Analysis of Dissolved Deals

In the first two weeks of this month, pharma firms dissolved four partnerships with biotech companies, continuing a trend that's been troubling the industry. Read More

Is CER the Rx for Personalized Medicine?

Infectious Disease Pipeline Thinner, but Inching Forward

Money Raised Year to Date

Money Raised By Biotech in 2011

Week in Review

Word on the Street

Week in Washington

FDA Approvals in April

Phase I Clinical Trials Update: April 2011

Phase II Clinical Trials Update: April 2011

Phase III Clinical Trials Update: April 2011

American Association for Cancer Research

American College of Cardiology

European Association for the Study of the Liver

Non-U.S. Clinical Trials & Regulatory Actions: April 2011

FDA Submissions, Approvals & Other Actions: April 2011

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...